Citadel Advisors LLC Makes New $26,000 Investment in Citius Oncology, Inc. (NASDAQ:CTOR)

Citadel Advisors LLC purchased a new position in shares of Citius Oncology, Inc. (NASDAQ:CTOR) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 22,699 shares of the company’s stock, valued at approximately $26,000.

Separately, IFP Advisors Inc boosted its position in Citius Oncology by 173.1% during the fourth quarter. IFP Advisors Inc now owns 22,215 shares of the company’s stock worth $26,000 after purchasing an additional 14,080 shares in the last quarter. 70.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CTOR shares. Maxim Group downgraded Citius Oncology from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 23rd. Citigroup downgraded Citius Oncology to a “hold” rating in a research report on Friday, May 23rd.

Citius Oncology Trading Up 3.5%

NASDAQ CTOR opened at $1.47 on Friday. The stock’s 50 day simple moving average is $0.86 and its 200-day simple moving average is $1.00. Citius Oncology, Inc. has a 1-year low of $0.55 and a 1-year high of $4.42. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.08 and a current ratio of 0.34.

Citius Oncology (NASDAQ:CTOR) last released its earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02).

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.